Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Cipher Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Kevin046on Feb 25, 2014 6:35pm
171 Views
Post# 22250408

RE:RE:RE:RE:RE:RE:RE:RE:RE:patience

RE:RE:RE:RE:RE:RE:RE:RE:RE:patience
smush74 wrote:
Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that its marketing partner for Absoricaä has reached a cumulative sales milestone in accordance with the parties' commercial agreement, triggering a one-time US$5.0 million (net) payment to Cipher. This revenue will be included in Cipher's Q4 2013 financial results, which the Company plans to report in late February.

Tomorrow you will get your answer if they have increased their percentage or not.


I really dont want to bash the stock but i believe everything has already price in the value into the current SP. SP raise over 10% prior to Q4 is something rare. Q4 might be over rated and perhaps might miss the expectation.. Tho it got 5mil payment but if sale was not as good, it still create negative impact. I missed the ride to $8 from low $7. Getting in now is risky.

IF tmr Q4 beats again, stock should go back to $9 in no time. if not we could see it back to low $7
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities